2,509
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Johnson & Johnson's recently active trials. Comparator arms are excluded.
- Guselkumab10 trials
- Amivantamab9 trials
- Lenalidomide7 trials
- Dexamethasone7 trials
- Daratumumab7 trials
- Bortezomib6 trials
Upcoming readouts
Next primary completion dates among Johnson & Johnson's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Jan 2027PLATYPUS: A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Pare…Phase 3
- Feb 2027ICONIC-PsA 2: A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experience…Phase 3
- Jun 2027TRIlogy-3: A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaPhase 2
- Aug 2027PALOMA-2: A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epider…Phase 2
- Oct 2027MACARONI-23: A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disea…Phase 3
- Dec 2027TRI Pro: A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With…Phase 2
Top therapeutic areas
Conditions studied most often across Johnson & Johnson's recently active trials.
- Multiple Myeloma14 trials
- Colitis, Ulcerative8 trials
- Crohn Disease7 trials
- Arthritis, Psoriatic6 trials
- Carcinoma, Non-Small-Cell Lung5 trials
- Psoriasis5 trials
Johnson & Johnson pipeline by phase
The main study drugs across 189 active trials Johnson & Johnson leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 332 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| NipocalimabM281 | 12 | 9 | Feb 2027 est. | NCT07438496 · NCT07217587 · NCT06741969 |
| Amivantamab | 11 | 8 | Dec 2026 est. | NCT07276399 · NCT06750094 · NCT06662786 |
| IcotrokinraJNJ-77242113 | 10 | 3 | Feb 2027 est. | NCT07196748 · NCT06934226 · NCT06878404 |
| Talquetamab | 8 | 2 | Jun 2027 est. | NCT06208150 · NCT05455320 · NCT06500884 |
| PasritamigJNJ-78278343 | 7 | 6 | Jan 2027 est. | NCT07225946 · NCT07164443 · NCT07319871 |
| RamantamigJNJ-79635322 | 7 | 6 | Apr 2027 est. | NCT07665450 · NCT07518186 · NCT07258511 |
| Teclistamab | 6 | 2 | Apr 2031 est. | NCT05572515 · NCT05552222 · NCT04557098 |
| Apalutamide | 4 | — | Oct 2026 est. | NCT05884398 · NCT03767244 · NCT04325828 |
| Daratumumab | 4 | — | Apr 2027 est. | NCT05438043 · NCT05083169 · NCT05250973 |
| Bleximenib | 3 | 2 | Oct 2026 est. | NCT06852222 · NCT05453903 · NCT04811560 |
| CetrelimabJNJ-63723283 | 3 | — | Dec 2026 est. | NCT04658862 · NCT05908734 · NCT02908906 |
| Erdafitinib | 3 | — | — | NCT03390504 · NCT02365597 · NCT03473743 |
| Ibrutinib | 3 | 1 | Dec 2026 est. | NCT03462719 · NCT01804686 · NCT05963074 |
| Lazertinib | 3 | — | Feb 2027 est. | NCT05388669 · NCT04988295 · NCT04077463 |
| TAR-200 | 3 | — | Sept 2029 est. | NCT06211764 · NCT05714202 · NCT04640623 |
| AAV5-hRKp.RPGR | 2 | — | Jun 2027 est. | NCT05926583 · NCT06646289 |
| JNJ-78934804 | 2 | 2 | Jun 2028 est. | NCT07577856 · NCT07577843 |
| Milvexian | 2 | — | Oct 2026 est. | NCT05757869 · NCT05702034 |
| Niraparib | 2 | — | — | NCT03748641 · NCT04577833 |
| Seltorexant | 2 | 2 | Dec 2026 est. | NCT07573176 · NCT06559306 |
| TAR-210 | 2 | 2 | Apr 2028 est. | NCT06919965 · NCT06319820 |
| Bortezomib | 1 | — | Feb 2029 est. | NCT04923893 |
| Esketamine | 1 | 1 | Apr 2031 est. | NCT07227454 |
| Esketamine 56 mg | 1 | 1 | Dec 2028 est. | NCT07716098 |
| Genetic: AAV5-hRKp.RPGR Intermediate Dose | 1 | — | Sept 2029 est. | NCT04794101 |
| Golimumab | 1 | — | — | NCT03596645 |
| Guselkumab Subcutaneous | 1 | — | Feb 2027 est. | NCT06260163 |
| LHRHa | 1 | — | Aug 2029 est. | NCT04557059 |
| Macitentan | 1 | 1 | Jan 2027 est. | NCT05179876 |
| Macitentan 10 mg | 1 | — | — | NCT04273945 |
| Selexipag | 1 | — | — | NCT04175600 |
| Ustekinumab | 1 | — | Sept 2027 est. | NCT05092269 |
Phase 29 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Amivantamab IV | 2 | 1 | Apr 2027 est. | NCT06120140 · NCT05379595 |
| JNJ-95597528 | 2 | — | Nov 2026 est. | NCT07746687 · NCT07230860 |
| Bedaquiline (TMC207) | 1 | 1 | Feb 2027 est. | NCT02354014 |
| JNJ-64042056 | 1 | — | Dec 2026 est. | NCT06544616 |
| JNJ-81201887 | 1 | 1 | Aug 2029 est. | NCT06635148 |
| JNJ-88545223 | 1 | 1 | Jun 2027 est. | NCT07321873 |
| Niraparib 200 mg | 1 | — | — | NCT03431350 |
| Rilpivirine | 1 | — | — | NCT02494986 |
| selexipag (Uptravi) | 1 | — | — | NCT03492177 |
Phase 127 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Erdafitinib Intravesical Delivery System | 2 | — | Mar 2028 est. | NCT05567185 · NCT05316155 |
| JNJ-80948543 | 2 | — | — | NCT06660563 · NCT05424822 |
| 14C-bleximenib | 1 | 1 | Sept 2026 est. | NCT07295951 |
| Ami-LC-MD | 1 | — | — | NCT04606381 |
| ARX517 | 1 | — | Dec 2026 est. | NCT04662580 |
| Aticaprant | 1 | 1 | Jun 2027 est. | NCT07615426 |
| Capmatinib | 1 | — | Apr 2027 est. | NCT05488314 |
| HLD-0117 | 1 | 1 | Apr 2028 est. | NCT07524855 |
| JNJ-101556143 Formulation 1 | 1 | 1 | Jul 2028 est. | NCT06800313 |
| JNJ-69086420 | 1 | — | Dec 2026 est. | NCT04644770 |
| JNJ-75348780 | 1 | — | Jan 2028 est. | NCT06788509 |
| JNJ-87562761 | 1 | — | Nov 2027 est. | NCT06604715 |
| JNJ-87801493 | 1 | — | — | NCT06139406 |
| JNJ-87890387 | 1 | 1 | Mar 2027 est. | NCT06178614 |
| JNJ-88549968 | 1 | 1 | Dec 2026 est. | NCT06150157 |
| JNJ-88998377 | 1 | — | Oct 2027 est. | NCT06470438 |
| JNJ-89402638 | 1 | 1 | Feb 2028 est. | NCT06663319 |
| JNJ-89853413 | 1 | — | Nov 2026 est. | NCT06618001 |
| JNJ-89862175 | 1 | 1 | Dec 2026 est. | NCT07223125 |
| JNJ-90009530 | 1 | — | Jan 2027 est. | NCT05784441 |
| JNJ-90014496 | 1 | — | Jul 2041 est. | NCT05421663 |
| JNJ-90189892 | 1 | 1 | Aug 2027 est. | NCT06651229 |
| JNJ-95437446 | 1 | 1 | Nov 2027 est. | NCT07107230 |
| JNJ-95566692 | 1 | 1 | Aug 2028 est. | NCT07308132 |
| JNJ-95804306 | 1 | 1 | May 2029 est. | NCT07572006 |
| JNJ-98768111 | 1 | 1 | Mar 2029 est. | NCT07746713 |
| Teclistamab (IV) | 1 | — | — | NCT03145181 |
Phase 43 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Guselkumab | 16 | 4 | Mar 2027 est. | NCT07654751 · NCT04929210 · NCT07499232 |
| Cilta-celJNJ-68284528 | 6 | 2 | Feb 2027 est. | NCT05201781 · NCT04181827 · NCT07149857 |
| Guselkumab (GUS) | 1 | 1 | Sept 2027 est. | NCT07310095 |
Combination backbones Prednisone (1 trial), Dexamethasone (1 trial). Established agents these trials combine with, listed separately from the drugs under study.
Derived from 189 active trials Johnson & Johnson leads; 175 name an intervention, folding into 71 phased drugs. This is ComplyRx's reading of the registry, not Johnson & Johnson's own pipeline disclosure.
Johnson & Johnson trials
The 50 most significant of Johnson & Johnson's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| LIBERTASA Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPCNCT05884398Apalutamide | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 420 est. | 12 Oct 2026 |
| LIBREXIA-STROKA Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKENCT05702034Milvexian | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 12,523 est. | 15 Oct 2026 |
| A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed TherapiesNCT05453903Bleximenib | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 196 est. | 30 Oct 2026 |
| BC RC DBA Study of Radical Cystectomy in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) and Muscle Invasive Bladder Cancer (MIBC) in KoreaNCT07735793 | — | Not yet scored | OngoingNot yet recruiting | 1 est. | 23 Nov 2026 |
| Evaluation of Approved Contact Lenses (CR-6657)NCT07819305Test (Senofilcon A) | Na | Not yet scored | OngoingNot yet recruiting | 150 est. | 3 Dec 2026 |
| A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative NeoplasmsNCT06150157JNJ-88549968 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 300 est. | 4 Dec 2026 |
| OPALAn Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative ColitisNCT02808780 | — | Not yet scored | OngoingActive, not recruiting | 535 est. | 10 Dec 2026 |
| Comparison of ACUVUE® OASYS MAX 1-Day Multifocal and DAILIES® AquaComfort Plus® MultifocalNCT07788521Senofilcon A | Na | Not yet scored | OngoingNot yet recruiting | 150 est. | 11 Dec 2026 |
| A Study of JNJ-89862175 for Treatment of Advanced Solid TumorsNCT07223125JNJ-89862175 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 360 est. | 15 Dec 2026 |
| SunRISe-2A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderNCT04658862Cetrelimab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 518 est. | 30 Dec 2026 |
| CHRYSALISStudy of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerNCT02609776Amivantamab | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 751 est. | 31 Dec 2026 |
| ARX517ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate CancerNCT04662580ARX517 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 183 est. | 31 Dec 2026 |
| A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate CancerNCT07319871Pasritamig | Phase 1 | Locked · track to reveal | OngoingRecruiting | 40 est. | 7 Jan 2027 |
| PLATYPUSA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionNCT05179876Macitentan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 280 est. | 31 Jan 2027 |
| ICONIC-PsA 2A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisNCT06807424Icotrokinra | Phase 3 | Locked · track to reveal | OngoingRecruiting | 750 est. | 10 Feb 2027 |
| QUASAR JrA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisNCT06260163Guselkumab Subcutaneous | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 112 est. | 10 Feb 2027 |
| cAMeLot-1A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)NCT04811560Bleximenib | Phase 1 | Locked · track to reveal | OngoingRecruiting | 420 est. | 26 Feb 2027 |
| CARTITUDE-2A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple MyelomaNCT04133636JNJ-68284528 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 208 est. | 26 Feb 2027 |
| FUZION CDA Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's DiseaseNCT05347095Guselkumab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 288 est. | 25 Mar 2027 |
| STARA Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial DiseaseNCT04929210Guselkumab | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 411 est. | 1 Apr 2027 |
| A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple MyelomaNCT04108195Daratumumab | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 290 est. | 7 Apr 2027 |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) AmyloidosisNCT05652335JNJ-79635322 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 180 est. | 19 Apr 2027 |
| TRIlogy-3A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaNCT07266441JNJ-79635322 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 157 est. | 14 Jun 2027 |
| GURUA Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World SettingNCT07220824 | — | Locked · track to reveal | OngoingRecruiting | 200 est. | 31 Jul 2027 |
| A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic NeoplasmsNCT06651229JNJ-90189892 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 155 est. | 5 Aug 2027 |
| PALOMA-2A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerNCT05498428Amivantamab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 520 est. | 17 Aug 2027 |
| MonumenTAL-8A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple MyelomaNCT06550895Cilta-cel | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 11 est. | 26 Aug 2027 |
| A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA TherapeuticallyNCT07654751Breast Milk Sample Collection | Phase 4 | Locked · track to reveal | OngoingRecruiting | 10 est. | 31 Aug 2027 |
| A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerNCT05818683Pasritamig | Phase 1 | Locked · track to reveal | OngoingRecruiting | 300 est. | 31 Aug 2027 |
| UNITEDA Long-term Extension Study of Ustekinumab in Pediatric ParticipantsNCT05092269Ustekinumab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 159 est. | 29 Sept 2027 |
| MACARONI-23A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseNCT05923073Guselkumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 120 est. | 27 Oct 2027 |
| A Study of JNJ-95437446 in Participants With Advanced-Stage Solid TumorsNCT07107230JNJ-95437446 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 400 est. | 18 Nov 2027 |
| TRI ProA Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple MyelomaNCT07589634Ramantamig | Phase 2 | Locked · track to reveal | OngoingRecruiting | 230 est. | 31 Dec 2027 |
| DAFFODILNipocalimab in Moderate to Severe Sjogren's DiseaseNCT06741969Nipocalimab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 655 est. | 1 Jan 2028 |
| AmiNAA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCNCT07586202Amivantamab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 68 est. | 2 Mar 2028 |
| MoonRISe-1A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder CancerNCT06319820TAR-210 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 641 est. | 28 Jun 2028 |
| Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate CancerNCT06800313JNJ-101556143 Formulation 1 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 190 est. | 11 Jul 2028 |
| KLK2-comPASA Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT07164443Pasritamig | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,203 est. | 18 Aug 2028 |
| A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid MalignanciesNCT07308132JNJ-95566692 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 340 est. | 31 Aug 2028 |
| PROGRESS-ROA Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in RomaniaNCT07582783 | — | Locked · track to reveal | OngoingRecruiting | 200 est. | 15 Sept 2028 |
| ICONIC-CDA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's DiseaseNCT07196722Icotrokinra | Phase 2 | Locked · track to reveal | OngoingRecruiting | 1,092 est. | 19 Sept 2028 |
| CHARGEA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's DiseaseNCT07499232Guselkumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 530 est. | 15 Nov 2028 |
| TRIlogy-4A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaNCT07258511JNJ-79635322 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 400 est. | 12 Dec 2028 |
| A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant DepressionNCT07716098Esketamine 56 mg | Phase 3 | Not yet scored | OngoingRecruiting | 348 est. | 27 Dec 2028 |
| A Study of DaratumumabNCT05438043Daratumumab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 213 est. | 31 Jan 2029 |
| CARTITUDE-5A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial TherapyNCT04923893Bortezomib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 743 est. | 14 Feb 2029 |
| A Study of JNJ-98768111 in Participants With Advanced Prostate CancerNCT07746713JNJ-98768111 | Phase 1 | Not yet scored | OngoingRecruiting | 100 est. | 16 Mar 2029 |
| A Study of JNJ-95804306 for Relapsed or Refractory Hematological MalignanciesNCT07572006JNJ-95804306 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 360 est. | 18 May 2029 |
| COPERNICUSA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT06667076Amivantamab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 480 est. | 23 May 2029 |
| OrigAMI-5A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck CancerNCT07276399Amivantamab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 500 est. | 18 Jun 2029 |